Quagen Pharmaceuticals

Halobetasol Propionate Ointment

Halobetasol Propionate Ointment

• Category: HUMAN PRESCRIPTION DRUG LABEL
• DEA Schedule: None
• Marketing Status: Abbreviated New Drug Application

INDICATIONS AND USAGE

Halobetasol Propionate Ointment 0.05% is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond two consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in children under 12 years of age is not recommended.

As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.